Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05615415 · ClinicalTrials.gov registry record
Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 (PASC) Using TSPO Positron Emission Tomography (PET) and MRI
A clinical trial of Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection, sponsored by NYU Langone Health.
- Active
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT05615415: Active study of Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection, sponsored by NYU Langone Health.
NCT05615415 is a study of Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05615415, a study of Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection, is active but no longer recruiting, sponsored by NYU Langone Health.
- ACTIVE NOT RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The overarching goal of this study is to develop PET/MR techniques for the diagnosis of neuropsychiatric post-acute sequelae (PASC) of SARS-CoV-2. The central hypothesis is that immunological and cerebrovascular dysfunction after acute SARS-CoV-2 infections mediate neuropsychiatric PASC (NP-PASC).
Primary Outcome
Binding of PET tracer to TSPO.
Conditions Studied
Interventions
- DRUG PET Tracer
- DRUG MRI Tracer
- DEVICE 3T PET/MRI
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-02-15 |
| Est. Completion | 2026-12-31 |
What the registry record for NCT05615415 still lists
NCT05615415 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 1 condition, with Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection appearing as the primary indexed condition, and to 3 interventions - of which PET Tracer is the first listed.
NCT05615415 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05615415 about?
NCT05615415 is a clinical study titled "Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 (PASC) Using TSPO Positron Emission Tomography (PET) and MRI". The overarching goal of this study is to develop PET/MR techniques for the diagnosis of neuropsychiatric post-acute sequelae (PASC) of SARS-CoV-2. The central hypothesis is that immunological and cerebrovascular dysfunction after acute SARS-CoV-2 infections mediate neuropsychiatric PASC (NP-PASC).
What is the current status of trial NCT05615415?
This trial is currently active not recruiting. The enrollment target is 30 participants. The study started on 2022-02-15. Estimated completion is 2026-12-31.
What conditions does trial NCT05615415 study?
This clinical trial studies the following conditions: Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection.
What interventions are being tested in trial NCT05615415?
The interventions under investigation include: PET Tracer (DRUG), MRI Tracer (DRUG), 3T PET/MRI (DEVICE).
Who is sponsoring clinical trial NCT05615415?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05615415 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI